{"disease":{"id":"generalized-seizures","name":"generalized seizures"},"drugs":{"marketed":[{"drug_id":"perampanel","indication_name":"Secondarily generalized seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fycompa","generic_name":"PERAMPANEL","company_name":"Catalyst Pharms","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic AMPA","drug_class":"Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]","quality_score":75,"revenue":"300","mechanism":"Fycompa works by blocking the AMPA glutamate receptor, which is involved in the transmission of nerve impulses."},{"drug_id":"carbamazepine","indication_name":"Generalized Tonic-Clonic Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tegretol","generic_name":"carbamazepine","company_name":"Novartis AG (originally Geigy)","drug_phase":"marketed","molecular_target":"Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4","drug_class":"Mood Stabilizer [EPC]","quality_score":62,"revenue":null,"mechanism":"Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain."},{"drug_id":"bat","indication_name":"Treatment of primary generalized tonic-clonic seizures in patients 2 years of age and older with epilepsy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fycompa","indication_name":"Secondarily generalized seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fycompa","company_name":"Eisai Inc.","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic AMPA","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03059329","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","phase":"","overall_status":"COMPLETED","enrollment_count":3809,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT01463306","title":"A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT03059381","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","phase":"","overall_status":"COMPLETED","enrollment_count":519,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT01747915","title":"A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT02849626","title":"Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT06657378","title":"A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures","phase":"","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT03288129","title":"Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT02307578","title":"An Extended Access Program (EAP) for Perampanel","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Eisai Inc.","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}